GRFS 250417 7.00P(GRFS250417P7000) Stock Price Today

0.57
+0.35+159.09%

15min DelayClose Apr 4 16:00 ET

0.57High0.40Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Movers and Shakers

Apr 2 20:03

Columns Today's Pre-Market Movers and Top Ratings | TSLA, DJT, WTF and More

Morning Movers
Gapping Up
$TTEC Holdings (TTEC.US)$ shares surged 29.36% in pre-market trading after the board expressed willingness to discuss CEO Kenneth Tuchman's proposal to acquire the company's shares for $6.85 each. Tuchman, who already owns about 58% of TTEC, made the offer in late September.
$Grifols (GRFS.US)$ shares rose 12.62% after Brookfield (BAM) resumed takeover talks with the Spanish pharmaceutical firm, as reporte...

Trytosaveabit

Oct 29, 2024 20:12

News

$Grifols (GRFS.US)$ Grifols Receives FDA Approval To Treat Surgical Bleeding In Pediatric Patients With Its Fibrin Sealant Solution
Benzinga· 3 mins ago

Trytosaveabit

Oct 3, 2024 20:12

If any seen that for the 40 seconds it was posted!

$Grifols (GRFS.US)$ I removed the post because i think the PR was tagged to the wrong ticker by the NEWS OUTLETT! And i want to be more safe and check a bit more!

Trytosaveabit

Aug 21, 2024 16:57

A bit added to older PR ( seeking backing ) is the new!

$Grifols (GRFS.US)$ Investing.com -- Shares of Grifols SA (BME:GRLS) (NASDAQ:GRFS) rose on Wednesday after Bloomberg News reported that Brookfield Asset Management (TSX:BAM) is seeking bank backing for up to €9.5 billion in debt to facilitate its potential take-private acquisition of the Spanish pharmaceutical producer

Trytosaveabit

Jul 29, 2024 20:04

News

$Grifols (GRFS.US)$ Benzinga· 2 mins ago
FDA Approves Expanded Label For Grifols' XEMBIFY, The First 20% SCIg For Treatment-Naïve Patients With Primary Humoral Immunodeficiencies; Approval Includes Biweekly Dosing Following Positive Phase 4 Data, Enhancing Flexibility And Convenience For Patients